These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 22509863)

  • 21. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey.
    Pisters R; Nieuwlaat R; Lane DA; Crijns HJ; Lip GY
    Thromb Haemost; 2013 Feb; 109(2):328-36. PubMed ID: 23179181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is there really misuse and abuse of dabigatran?
    Eikelboom JW; Hankey GJ
    Med J Aust; 2013 Apr; 198(7):358-9. PubMed ID: 23581946
    [No Abstract]   [Full Text] [Related]  

  • 23. Direct oral anticoagulants in atrial fibrillation.
    Noll G; Noll S; Hürlimann D
    Semin Hematol; 2014 Apr; 51(2):139-46. PubMed ID: 24861798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation.
    Lane DA; Wood K
    Circulation; 2015 Apr; 131(16):e412-5. PubMed ID: 25901074
    [No Abstract]   [Full Text] [Related]  

  • 25. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
    Eikelboom JW; Wallentin L; Connolly SJ; Ezekowitz M; Healey JS; Oldgren J; Yang S; Alings M; Kaatz S; Hohnloser SH; Diener HC; Franzosi MG; Huber K; Reilly P; Varrone J; Yusuf S
    Circulation; 2011 May; 123(21):2363-72. PubMed ID: 21576658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dabigatran in patients with nonvalvular atrial fibrillation.
    Gage L
    J Am Coll Cardiol; 2011 Jul; 58(5):551; author reply 551. PubMed ID: 21777759
    [No Abstract]   [Full Text] [Related]  

  • 27. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
    Coyle D; Coyle K; Cameron C; Lee K; Kelly S; Steiner S; Wells GA
    Value Health; 2013 Jun; 16(4):498-506. PubMed ID: 23796283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Food and Drug Administration decision not to approve the 110 mg dose of dabigatran: give us a way out.
    Kowey PR; Naccarelli GV
    Am J Med; 2012 Aug; 125(8):732. PubMed ID: 22608987
    [No Abstract]   [Full Text] [Related]  

  • 29. Faculty of Consulting Physicians of South Africa (FCPSA): saving brain with dabigatran.
    Aalbers J; Hardy G
    Cardiovasc J Afr; 2012 Jul; 23(6):350-1. PubMed ID: 23091827
    [No Abstract]   [Full Text] [Related]  

  • 30. Atrial fibrillation and anticoagulation management: a wake-up call to practitioners, patients, and policymakers.
    Fanikos J
    J Med Econ; 2013 Oct; 16(10):1190-2. PubMed ID: 23919663
    [No Abstract]   [Full Text] [Related]  

  • 31. Dabigatran "non-inferior" to warfarin, but only just.
    BMJ; 2013 Feb; 346():f1219. PubMed ID: 23447339
    [No Abstract]   [Full Text] [Related]  

  • 32. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
    Zalesak M; Siu K; Francis K; Yu C; Alvrtsyan H; Rao Y; Walker D; Sander S; Miyasato G; Matchar D; Sanchez H
    Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):567-74. PubMed ID: 23922182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trial.
    Hori M; Connolly SJ; Ezekowitz MD; Reilly PA; Yusuf S; Wallentin L;
    Circ J; 2011; 75(4):800-5. PubMed ID: 21436594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Stroke prevention after stroke in patients with atrial fibrillation: a case-based review].
    Kovács T
    Orv Hetil; 2014 Oct; 155(42):1655-60. PubMed ID: 25305723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of bleeding complications post-ablation between warfarin and dabigatran.
    Snipelisky D; Kauffman C; Prussak K; Johns G; Venkatachalam K; Kusumoto F
    J Interv Card Electrophysiol; 2012 Oct; 35(1):29-33. PubMed ID: 22869389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
    Chevalier J; Delaitre O; Hammès F; de Pouvourville G
    Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
    Gong IY; Kim RB
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S24-33. PubMed ID: 23790595
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation.
    Shah SV; Gage BF
    Circulation; 2011 Jun; 123(22):2562-70. PubMed ID: 21606397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
    Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dabigatran and mechanical heart valves--not as easy as we hoped.
    Hylek EM
    N Engl J Med; 2013 Sep; 369(13):1264-6. PubMed ID: 23991659
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.